KalVista Pharmaceuticals Reports Fiscal First Quarter Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Marvell shares jump after giving Google warrants amid custom chip deal
KalVista Pharmaceuticals (KALV) Reports Q1 Loss of $0.47/Share
September 14, 2018 7:33 AM EDTKalVista Pharmaceuticals (NASDAQ: KALV) reported Q1 EPS of ($0.47), versus ($0.51) reported last year. Revenue for the quarter came in at $3.7 million, versus $10 thousand reported last year.
For earnings history and earnings-related data on KalVista Pharmaceuticals (KALV) click here.
... More